

Leonardo De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6487862/publications.pdf>

Version: 2024-02-01

192
papers

8,492
citations

87886

38
h-index

48312

88
g-index

215
all docs

215
docs citations

215
times ranked

9716
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
2	Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment. <i>American Journal of Medicine</i> , 2006, 119, S3-S10.	1.5	339
3	Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. <i>Intensive Care Medicine</i> , 2005, 31, 638-644.	8.2	332
4	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. <i>Circulation</i> , 2006, 114, 1202-1213.	1.6	320
5	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
6	Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 11-17.	1.6	255
7	Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. <i>European Heart Journal</i> , 2009, 30, 2193-2203.	2.2	245
8	Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials. <i>American Journal of Cardiology</i> , 2005, 96, 3-9.	1.6	217
9	Reassessment of Dobutamine, Dopamine, and Milrinone in the Management of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 47-58.	1.6	207
10	Evidence-based use of levosimendan in different clinical settings. <i>European Heart Journal</i> , 2006, 27, 1908-1920.	2.2	193
11	Cardiac Hemodynamic and Coronary Angiographic Characteristics of Patients Being Evaluated for Liver Transplantation. <i>American Journal of Cardiology</i> , 2006, 98, 178-181.	1.6	188
12	Hyponatremia in Patients with Heart Failure. <i>American Journal of Cardiology</i> , 2005, 96, 19-23.	1.6	169
13	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2019, 394, 1169-1180.	13.7	155
14	Overview of Vasopressin Receptor Antagonists in Heart Failure Resulting in Hospitalization. <i>American Journal of Cardiology</i> , 2005, 96, 24-33.	1.6	142
15	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 254-263.	2.8	124
16	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. <i>Circulation</i> , 2018, 137, 2435-2445.	1.6	116
17	Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. <i>European Journal of Heart Failure</i> , 2015, 17, 1124-1132.	7.1	95
18	Mechanisms of Atherothrombosis and Vascular Response to Primary Percutaneous Coronary Intervention in Women Versus Men With Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 958-968.	2.9	89

#	ARTICLE	IF	CITATIONS
19	The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF Study. <i>Journal of Cardiac Failure</i> , 2009, 15, 377-384.	1.7	88
20	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. <i>EuroIntervention</i> , 2017, 13, 459-466.	3.2	83
21	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 441-452.	1.0	81
22	Nonpharmacologic care of heart failure: counseling, dietary restriction, rehabilitation, treatment of sleep apnea, and ultrafiltration. <i>American Journal of Cardiology</i> , 2003, 91, 41-50.	1.6	70
23	Review of Current and Investigational Pharmacologic Agents for Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2007, 99, S4-S23.	1.6	70
24	Contemporary Trends and Age-specific Sex Differences in Management and Outcome for Patients With ST-segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	67
25	Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. <i>Heart Failure Reviews</i> , 2007, 12, 97-104.	3.9	60
26	Endoscopic dilation of benign colorectal anastomotic stricture after low anterior resection: a prospective comparison study of two balloon types. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 347-350.	1.0	59
27	Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. <i>American Heart Journal</i> , 2005, 150, 563-568.	2.7	57
28	A decade of changes in clinical characteristics and management of elderly patients with non-ST elevation myocardial infarction admitted in Italian cardiac care units. <i>Open Heart</i> , 2014, 1, e000148.	2.3	57
29	EUS imaging of the arteria lusoria: Case series and review. <i>Gastrointestinal Endoscopy</i> , 2000, 52, 670-673.	1.0	54
30	Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. <i>International Journal of Cardiology</i> , 2014, 177, 881-885.	1.7	50
31	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 152-167.	3.0	50
32	Comparison of treatment outcomes between biliary plastic stent placements with and without endoscopic sphincterotomy for inoperable malignant common bile duct obstruction. <i>World Journal of Gastroenterology</i> , 2004, 10, 1212.	3.3	48
33	Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. <i>Thrombosis Research</i> , 2007, 120, 631-634.	1.7	46
34	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 229-243.	3.0	46
35	Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology. <i>Acute Cardiac Care</i> , 2011, 13, 56-67.	0.2	45
36	Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. <i>European Heart Journal</i> , 2018, 39, 2448-2456.	2.2	44

#	ARTICLE	IF	CITATIONS
37	Overview of emerging pharmacologic agents for acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2008, 10, 201-213.	7.1	39
38	Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008325.	3.9	39
39	The effect of thrombectomy on myocardial blush in primary angioplasty: The randomized evaluation of thrombus aspiration by two thrombectomy devices in acute myocardial infarction (RETAMI) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 84-91.	1.7	38
40	Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study. <i>Diabetes Care</i> , 2008, 31, 15-19.	8.6	38
41	Early elevation of interleukin-1 β and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. <i>Thrombosis Research</i> , 2006, 117, 659-664.	1.7	37
42	Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study. <i>Circulation</i> , 2014, 129, 1104-1112.	1.6	37
43	Effects of Levosimendan on Left Ventricular Diastolic Function After Primary Angioplasty for Acute Anterior Myocardial Infarction: A Doppler Echocardiographic Study. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 172-177.	2.8	36
44	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018, 69, 795-802.	1.8	35
45	Interobserver agreement in contrast harmonic endoscopic ultrasound. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1063-1069.	2.8	31
46	Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). <i>European Journal of Internal Medicine</i> , 2021, 85, 1-13.	2.2	31
47	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. <i>Journal of the American Heart Association</i> , 2021, 10, e022125.	3.7	31
48	Pharmacological treatment of chronic heart failure. <i>Heart Failure Reviews</i> , 2006, 11, 109-123.	3.9	29
49	Evaluation of Infarct-Related Coronary Artery Patency and Microcirculatory Function After Facilitated Percutaneous Primary Coronary Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1284-1291.	2.9	29
50	Immunosuppressive Therapy with Oral Prednisone to Prevent Restenosis after PCI. A Multicenter Randomized Trial. <i>American Journal of Medicine</i> , 2011, 124, 434-443.	1.5	29
51	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. <i>Europace</i> , 2019, 21, 230-238.	1.7	27
52	Endoscopic treatment of pancreatico-biliary malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 127-135.	4.4	25
53	Current management and treatment of patients with stable coronary artery diseases presenting to cardiologists in different clinical contexts: A prospective, observational, nationwide study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 43-53.	1.8	25
54	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.1	25

#	ARTICLE	IF	CITATIONS
55	Effects of Glucose-Insulin-Potassium Infusion on Myocardial Perfusion and Left Ventricular Remodeling in Patients Treated With Primary Angioplasty for ST-Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 98, 1349-1353.	1.6	24
56	Management of acute coronary syndromes in older adults. <i>European Heart Journal</i> , 2022, 43, 1542-1553.	2.2	24
57	External applicability of the ISCHEMIA trial: an analysis of a prospective, nationwide registry of patients with stable coronary artery disease. <i>EuroIntervention</i> , 2020, 16, e966-e973.	3.2	24
58	Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up. <i>International Journal of Cardiology</i> , 2005, 102, 447-454.	1.7	23
59	Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. <i>American Heart Journal</i> , 2016, 176, 44-52.	2.7	23
60	Optical coherence tomography for characterization of cardiac allograft vasculopathy in late survivors of pediatric heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 74-79.	0.6	23
61	Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. <i>International Journal of Cardiology</i> , 2020, 316, 229-235.	1.7	23
62	High-density lipoprotein levels and risk of cardiovascular events. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 575-586.	1.5	22
63	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 168-178.	3.0	22
64	Quality of bowel cleansing in hospitalized patients undergoing colonoscopy: A multicentre prospective regional study. <i>Digestive and Liver Disease</i> , 2015, 47, 669-674.	0.9	22
65	Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 248, 369-375.	1.7	22
66	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	2.2	22
67	Early and Long-Term Outcomes After Combined Percutaneous Revascularization in Patients With Carotid and Coronary Artery Stenoses. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 560-568.	2.9	20
68	A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	20
69	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). <i>American Journal of Cardiology</i> , 2019, 123, 1610-1619.	1.6	20
70	Stress-rest myocardial perfusion SPECT for functional assessment of coronary arteries with anomalous origin or course. <i>Journal of Nuclear Medicine</i> , 2004, 45, 532-6.	5.0	20
71	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 198-213.	3.0	18
72	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. <i>International Journal of Cardiology</i> , 2018, 273, 8-14.	1.7	18

#	ARTICLE	IF	CITATIONS
73	COVID-19, Vaccines, and Thrombotic Events: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 948.	2.4	18
74	Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender. <i>Clinical Research in Cardiology</i> , 2016, 105, 421-431.	3.3	17
75	Individual patient-data meta-analysis comparing clinical outcome in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention with or without prior thrombectomy. ATTEMPT study: A pooled Analysis of Trials on Thrombectomy in acute Myocardial infarction based on individual Patient data. <i>Vascular Health and Risk Management</i> , 2009, 5, 243.	2.3	16
76	Appropriateness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. <i>BMJ Open</i> , 2017, 7, e016909.	1.9	16
77	Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. <i>EuroIntervention</i> , 2009, 5, 250-254.	3.2	16
78	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1-9.	1.7	15
79	Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 334-342.	4.0	14
80	Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. <i>International Journal of Cardiology</i> , 2021, 328, 22-28.	1.7	14
81	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 232-244.	3.0	13
82	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (very thin stents for patients with left main or Tj ETQq0 0 0 rgBT 10 Overlock 10 Tf 50 32	1.0	13
83	Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 94-103.	3.0	13
84	Effects of abciximab and preprocedural glyceimic control in diabetic patients undergoing elective coronary stenting. <i>American Heart Journal</i> , 2005, 149, 1135.e11-1135.e18.	2.7	12
85	New Monodimensional Transthoracic Echocardiographic Sign of Left Atrial Appendage Function. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 324-332.	2.8	12
86	Relationship Between Hiatal Hernia and Inguinal Hernia. <i>Digestive Diseases and Sciences</i> , 2004, 49, 243-247.	2.3	11
87	Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 1034-1042.	1.5	11
88	Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 469-473.	1.5	11
89	Evaluation and management of special subgroups after primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, S22-S27.	2.7	11
90	Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 12-14.	3.0	11

#	ARTICLE	IF	CITATIONS
91	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	2.6	11
92	Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). <i>Journal of Clinical Medicine</i> , 2021, 10, 4185.	2.4	11
93	Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. <i>BMJ Open</i> , 2020, 10, e041044.	1.9	11
94	Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. <i>American Journal of Cardiology</i> , 2020, 125, 491-499.	1.6	10
95	Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors. <i>Kardiologia Polska</i> , 2020, 78, 850-860.	0.6	10
96	Feasibility and safety of transradial approach and bivalirudin treatment in elderly patients undergoing early invasive strategy for ACS. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 351-352.	1.5	9
97	Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 40-48.	2.4	9
98	Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease. <i>European Journal of Internal Medicine</i> , 2019, 59, 70-76.	2.2	9
99	Fifteen-Year Trends of Cardiogenic Shock and Mortality in Patients with Diabetes and Acute Coronary Syndromes. <i>American Journal of Medicine</i> , 2020, 133, 331-339.e2.	1.5	9
100	Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 149-157.	2.0	9
101	Impact of age, gender and heart failure on mortality trends after acute myocardial infarction in Italy. <i>International Journal of Cardiology</i> , 2022, 348, 147-151.	1.7	9
102	Rationale and design of the Randomized comparison of XiEnce V and Multilink VisioN coronary stents in the same multivessel patient with chronic kidney disease (RENAL-DES) study. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 310-317.	1.5	8
103	Coronary plaque composition assessed by intravascular ultrasound virtual histology: Association with long-term clinical outcomes after heart transplantation in young adult recipients. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 70-77.	1.7	8
104	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 580-589.	1.5	8
105	Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study. <i>PLoS ONE</i> , 2018, 13, e0199770.	2.5	8
106	Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 352-359.	3.0	8
107	Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?. <i>Open Heart</i> , 2021, 8, e001677.	2.3	8
108	Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). <i>American Journal of Cardiology</i> , 2021, 156, 16-23.	1.6	8

#	ARTICLE	IF	CITATIONS
109	Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials. <i>Acute Cardiac Care</i> , 2007, 9, 10-21.	0.2	7
110	Clinical implications and management of bleeding events in patients with acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 677-686.	1.5	7
111	Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2015, 116, 660-668.	1.6	7
112	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2018, 41, 1075-1083.	1.8	7
113	Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. <i>IJC Heart and Vasculature</i> , 2019, 22, 39-45.	1.1	7
114	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. <i>European Journal of Internal Medicine</i> , 2020, 74, 55-60.	2.2	7
115	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-8.	2.5	7
116	Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study. <i>European Journal of Internal Medicine</i> , 2021, 88, 28-34.	2.2	7
117	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e023454.	3.7	7
118	Comparison Between Sirolimus- and Paclitaxel-Eluting Stent in T-Cell Subsets Redistribution. <i>American Journal of Cardiology</i> , 2006, 97, 494-498.	1.6	6
119	Hyponatremia in acute heart failure syndromes: A potential therapeutic target. <i>Current Heart Failure Reports</i> , 2007, 4, 207-213.	3.3	6
120	Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study. <i>Acute Cardiac Care</i> , 2008, 10, 93-99.	0.2	6
121	Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. <i>Current Medical Research and Opinion</i> , 2012, 28, 203-211.	1.9	6
122	Body mass index, gender, and clinical outcome among hypertensive and diabetic patients with stage A/B heart failure. <i>Obesity</i> , 2013, 21, E500-7.	3.0	6
123	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E129-39.	1.7	6
124	Percutaneous Treatment of Coronary Bifurcation Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	6
125	Patients with non-ST segment elevation acute coronary syndromes managed without coronary revascularization: A population needing treatment improvement. <i>International Journal of Cardiology</i> , 2017, 245, 35-42.	1.7	6
126	High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction. A nationwide retrospective cohort study. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	6

#	ARTICLE	IF	CITATIONS
127	The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 391-398.	2.0	6
128	COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 513-520.	4.0	6
129	Clinical characteristics, management and outcomes of patients with acute coronary syndrome and atrial fibrillation: real-world data from two nationwide registries in Italy. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 99-105.	1.5	6
130	Temporal Trends in Invasive Management and In-Hospital Mortality of Patients With Non-ST Elevation Acute Coronary Syndromes and Chronic Kidney Disease. <i>Angiology</i> , 2021, 72, 236-243.	1.8	6
131	Association of Sex with Outcome in Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Medicine</i> , 2021, 134, 1135-1141.e1.	1.5	6
132	Congestion in acute heart failure syndromes: importance of early recognition and treatment. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7, 69-74.	1.4	6
133	Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: data from the BLITZ study. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 1045-1051.	1.5	5
134	A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) – study design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 192-199.	1.5	5
135	Long-term outcome of provisional side-branch stenting for the treatment of unprotected distal left main coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 765-772.	1.7	5
136	Coronary risk in candidates for abdominal aortic aneurysm repair. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 817-821.	1.5	5
137	How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study. <i>Clinical Cardiology</i> , 2019, 42, 1113-1120.	1.8	5
138	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) <i>TJ</i> <i>ETQq000rgBT /Overlock 10 Tf 5</i>	1.7	5
139	Composite trends of cardiogenic shock complicating acute myocardial infarction. <i>European Journal of Heart Failure</i> , 2020, 22, 673-675.	7.1	5
140	Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. <i>Clinical Cardiology</i> , 0, , .	1.8	5
141	Congenital coronary artery anomaly simulating an acute aortic dissection. <i>Heart</i> , 2004, 90, e11-e11.	2.9	4
142	Inotropic agents in advanced heart failure: Repetita iuvant?. <i>International Journal of Cardiology</i> , 2014, 176, 6-7.	1.7	4
143	One-year outcome from an all-comers population of patients with <sc>ST</sc>-segment elevation myocardial infarction treated with biolimus-eluting stent with biodegradable polymer. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 352-358.	1.7	4
144	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). <i>European Heart Journal Supplements</i> , 2017, 19, D130-D150.	0.1	4

#	ARTICLE	IF	CITATIONS
145	Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e45-e47.	3.0	4
146	Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment. <i>Cardiology Journal</i> , 2022, 29, 850-857.	1.2	4
147	Risk stratification and secondary prevention post-myocardial infarction: insights from the EYESHOT Post-MI study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 478-485.	1.5	4
148	Rotational atherectomy in the distal left anterior descending coronary artery through an internal mammary artery graft. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 368-372.	1.5	3
149	Is the use of risk scores an indicator of guideline adherence for patients with acute coronary syndromes? Insights from the EYESHOT Registry. <i>International Journal of Cardiology</i> , 2015, 187, 80-83.	1.7	3
150	Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 336-343.	1.9	3
151	Fate of Nonculprit Plaques in Patients With STEMI Undergoing Primary PCI Followed by Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 827-829.	5.3	3
152	Procedural Characteristics for the Optimization of Dual Antiplatelet Therapy—Duration. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2464-2466.	2.9	3
153	Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization. <i>Heart and Vessels</i> , 2020, 35, 30-37.	1.2	3
154	Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 522-529.	1.7	3
155	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 881-889.	1.5	3
156	Characteristics and Outcome of Patients ≥75 Years of Age With Prior Coronary Artery Bypass Grafting Admitted for an Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2020, 125, 1788-1793.	1.6	3
157	Current management and prognosis of patients with recurrent myocardial infarction. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 731.	1.4	3
158	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <i>Journal of Clinical Medicine</i> , 2021, 10, 1923.	2.4	3
159	Impact of history of depression on 1-year outcomes in patients with chronic coronary syndromes: An analysis of a contemporary, prospective, nationwide registry. <i>International Journal of Cardiology</i> , 2021, 331, 273-280.	1.7	3
160	Regional differences and Italian charter to expand the primary angioplasty service. <i>EuroIntervention</i> , 2012, 8, P80-P85.	3.2	3
161	One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 410-416.	2.1	3
162	Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 393-401.	2.6	3

#	ARTICLE	IF	CITATIONS
163	Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 512.	2.4	3
164	Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 874087.	2.4	3
165	Antithrombotic therapy in atrial fibrillation: beyond the AFFIRM study. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 505-513.	1.5	2
166	PEGASUS study. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e100-e104.	1.5	2
167	Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. <i>Journal of Clinical Medicine</i> , 2021, 10, 1721.	2.4	2
168	Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 442-444.	3.0	2
169	Incidence, Characteristics, and Management of Patients with Recurrent Myocardial Infarctions: Insights from the EYESHOT POST-MI. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-8.	1.2	2
170	Impact of eGFR rate on 1-year all-cause mortality in patients with stable coronary artery disease. <i>European Journal of Internal Medicine</i> , 2022, 101, 98-105.	2.2	2
171	ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. <i>European Heart Journal Supplements</i> , 2022, 24, C254-C271.	0.1	2
172	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. <i>Journal of Personalized Medicine</i> , 2022, 12, 990.	2.5	2
173	The Stent for Life project in Italy. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 850-855.	1.5	1
174	Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?. <i>American Journal of Medicine</i> , 2017, 130, e515.	1.5	1
175	Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1563-1567.	1.9	1
176	ANMCO POSITION PAPER: Timing of coronary angiography in non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal Supplements</i> , 2021, 23, C196-C203.	0.1	1
177	Evolution of STEMI network in Italy. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 392-399.	0.7	1
178	Periprocedural Myocardial Injury in High-Risk Patients With NSTEMI Pretreated With Ticagrelor for Less or More Than 6 Hours Before PCI. <i>Journal of Clinical Pharmacology</i> , 2021, , .	2.0	1
179	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1086-1094.	1.7	1
180	Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention?. <i>Cardiology</i> , 2022, 147, 133-136.	1.4	1

#	ARTICLE	IF	CITATIONS
181	ANMCO position paper – Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation™. European Heart Journal Supplements, 2022, 24, C278-C288.	0.1	1
182	Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients with Acute Ischemic Stroke with and without Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 3894.	2.4	1
183	Proper use of glycoprotein IIb/IIIa inhibitors in patients with non-ST elevation acute coronary syndromes undergoing coronary angiography: frankly, my dear, I don't give a damn. Journal of Cardiovascular Medicine, 2006, 7, 166-168.	1.5	0
184	Unusual treatment of coronary artery aneurysm. Journal of Cardiovascular Medicine, 2008, 9, 864-865.	1.5	0
185	Percutaneous coronary intervention of unprotected left main and bifurcation in octogenarians: Subanalysis from RAIN (veRy thin stents for patients with left mAIn or bifurcatioN in real life). Catheterization and Cardiovascular Interventions, 2021, 97, 755-763.	1.7	0
186	Comparing the Prognostic Impact of Prediabetes with Diabetes in a Nationwide Cohort of Patients with Chronic Coronary Syndromes: An Analysis of the START Registry. Cardiology, 2021, 146, 547-555.	1.4	0
187	Reply: Applicability of ISCHEMIA in real-world practice: where to START?. EuroIntervention, 2021, 17, e183-e184.	3.2	0
188	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. Biomedicine and Pharmacotherapy, 2021, 140, 111783.	5.6	0
189	Fondaparinux During Intra-Aortic Balloon Pump Counterpulsation in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Heart Lung and Circulation, 2021, 30, 1545-1551.	0.4	0
190	The History of Research on Coronary Stenting. , 2013, , 167-179.		0
191	A prospective registry on carotid artery revascularisation selected by consensus of a cardiovascular team. EuroIntervention, 2014, 9, 1294-1300.	3.2	0
192	Impact of myocardial revascularization on long-term outcomes in a nationwide cohort of first acute myocardial infarction survivors. European Heart Journal Supplements, 2022, 24, C225-C232.	0.1	0